X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (523) 523
index medicus (455) 455
anaplastic lymphoma kinase (377) 377
receptor protein-tyrosine kinases - antagonists & inhibitors (263) 263
oncology (261) 261
animals (200) 200
lung neoplasms - drug therapy (199) 199
carcinoma, non-small-cell lung - drug therapy (180) 180
crizotinib (174) 174
receptor protein-tyrosine kinases - genetics (165) 165
protein kinase inhibitors - pharmacology (161) 161
protein kinase inhibitors - therapeutic use (160) 160
cancer (156) 156
cell line, tumor (145) 145
mutation (138) 138
receptor protein-tyrosine kinases - metabolism (136) 136
lymphomas (133) 133
female (132) 132
lung neoplasms - genetics (129) 129
antineoplastic agents - therapeutic use (128) 128
hemic and lymphatic diseases (118) 118
mice (109) 109
carcinoma, non-small-cell lung - genetics (108) 108
male (107) 107
antineoplastic agents - pharmacology (106) 106
cell lung-cancer (105) 105
chemotherapy (104) 104
alk (103) 103
lung cancer (96) 96
lung neoplasms - pathology (96) 96
lung cancer, non-small cell (90) 90
protein-tyrosine kinases - antagonists & inhibitors (84) 84
gene (76) 76
pyrazoles - therapeutic use (75) 75
pyridines - therapeutic use (75) 75
article (74) 74
eml4-alk fusion gene (74) 74
lung-cancer (74) 74
identification (73) 73
lung neoplasms - enzymology (73) 73
middle aged (72) 72
neuroblastoma (71) 71
pyridines - pharmacology (71) 71
care and treatment (70) 70
molecular targeted therapy (69) 69
pharmacology & pharmacy (69) 69
resistance (69) 69
carcinoma, non-small-cell lung - pathology (68) 68
protein-tyrosine kinases - metabolism (68) 68
tumors (68) 68
receptor tyrosine kinase (67) 67
research (67) 67
tyrosine kinase (67) 67
kinases (65) 65
cell biology (64) 64
protein-tyrosine kinases - genetics (63) 63
pyrazoles - pharmacology (63) 63
carcinoma, non-small-cell lung - enzymology (62) 62
activating mutations (61) 61
adult (61) 61
biochemistry & molecular biology (61) 61
cell proliferation - drug effects (60) 60
genetic aspects (60) 60
npm-alk (60) 60
apoptosis (59) 59
mutations (58) 58
drug resistance, neoplasm (57) 57
apoptosis - drug effects (56) 56
anaplastic lymphoma (54) 54
non-small cell lung cancer (54) 54
open-label (54) 54
tyrosine (54) 54
lymphoma (53) 53
oncogene proteins, fusion - genetics (53) 53
signal transduction (53) 53
acquired-resistance (52) 52
health aspects (52) 52
xenograft model antitumor assays (52) 52
hematology (51) 51
non-hodgkins-lymphoma (51) 51
protein kinase inhibitors - chemistry (51) 51
anaplastic lymphoma kinase - antagonists & inhibitors (50) 50
chemistry, medicinal (50) 50
expression (50) 50
inhibitor (50) 50
lymphoma, large-cell, anaplastic - pathology (50) 50
signal transduction - drug effects (49) 49
lung neoplasms - metabolism (48) 48
neoplasms - drug therapy (48) 48
proteins (48) 48
aged (47) 47
phosphorylation (47) 47
fusion (46) 46
receptor protein-tyrosine kinases (46) 46
ceritinib (45) 45
large-cell lymphoma (45) 45
analysis (44) 44
c-met (44) 44
inhibitors (44) 44
metastasis (44) 44
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 12, pp. 1199 - 1206
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
MEDICINE, GENERAL & INTERNAL | CERITINIB | EML4-ALK FUSION GENE | RESISTANCE | OPEN-LABEL | KINASE INHIBITOR | SINGLE-ARM | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2018, Volume 19, Issue 12, pp. 1654 - 1667
Journal Article
Journal Article
Molecular Cancer, ISSN 1476-4598, 02/2018, Volume 17, Issue 1, pp. 52 - 52
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 1126 - 15
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article